Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Company Overview

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Key Stats

• Today's Range: $8.37 to $8.37
• 50-Day Range: $8.33 to $8.40
• 52-Week Range: $2.66 to $8.55
• Volume: N/A
• Average Volume: 2.97 million shs
• Market Capitalization: $401.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Concert Pharmaceuticals Stock Analysis - MarketRank™

Concert Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 889th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Concert Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Concert Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Concert Pharmaceuticals is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Concert Pharmaceuticals is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Concert Pharmaceuticals has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CNCE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Concert Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Concert Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.93

Short Interest

There is no current short interest data available for CNCE.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.40

News Coverage This Week

MarketBeat has tracked 4 news articles for Concert Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Concert Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.33% of the stock of Concert Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.63% of the stock of Concert Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNCE Stock Analysis - Frequently Asked Questions

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analysts' expectations of $0.25 million.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX) and Celldex Therapeutics (CLDX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 9/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNCE
• CUSIP: N/A
• CIK: 1367920
• Web: www.concertpharma.com
• Phone: (781) 860-0045
• Fax: 302-636-5454
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-80,050,000.00
• Net Margins: N/A
• Pretax Margin: -300,735.69%
• Return on Equity: -109.43%
• Return on Assets: -76.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.03
• Quick Ratio: 9.03

Sales & Book Value

• Annual Sales: $32.58 million
• Price / Sales: 12.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.24 per share
• Price / Book: 2.58

Miscellaneous

• Outstanding Shares: 47,940,000
• Free Float: 42,507,000
• Market Cap: $401.26 million
• Optionable: Optionable
• Beta: 0.52